



Jos H Beijnen

Contact

Jos H Beijnen

Publications (12)

Groenland S, Verheijen R, Jörger M, Mathijssen R, Sparreboom A, Beijnen J, Beumer J, Steeghs N, Huitema A. Precision Dosing of Targeted Therapies Is Ready for Prime Time. *Clin Cancer Res* 2021; 27:6644-6652.

Jacobs B, Deenen M, Joerger M, Rosing H, de Vries N, Meulendijks D, Cats A, Beijnen J, Schellens J, Huitema A. Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis. *CPT Pharmacometrics Syst Pharmacol* 2019; 8:940-950.

Crombag M, Koolen S, Wijngaard S, Jörger M, Dorlo T, van Erp N, Mathijssen R, Beijnen J, Huitema A. Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?. *Pharm Res* 2019; 36:163.

Crombag M, Beijnen J, Mathijssen R, van Erp N, Dorlo T, Schellens J, Jörger M, Wijngaard S, Koolen S, de Vries Schultink A, Huitema A. Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study. *Pharm Res* 2019; 36:33.

Crombag M, Jörger M, Thürlimann B, Schellens J, Beijnen J, Huitema A. Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. *Cancers (Basel)* 2016; 8

Jörger M, Kraff S, Huitema A, Feiss G, Moritz B, Schellens J, Beijnen J, Jaehde U. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study. *Clin Pharmacokinet* 2012; 51:607-17.

Jörger M, Beijnen J, Huitema A, Vincent A, Smits P, Doodeman V, Bard M, Haitjema T, Smit E, Baas P, Burgers S, Schellens J. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. *Cancer* 2011; 118:2466-75.

Buikhuisen W, Burgers J, Vincent A, Schellens J, Beijnen J, Smit E, Jörger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?. *J Clin Oncol* 2010; 28:e482-3; author reply e484.

Jörger M, Hollema H, Féty R, Van der Vijgh W, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers A, Twelves C, Beijnen J, Boddy A, Calvert H, Jodrell D, Huitema A, Richel D, Ditttrich C, Pavlidis N, Briasoulis E, Vermorken J, Strocchi E, Martoni A, Sorio R, Sleeboom H, Izquierdo M, Schellens J. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2007; 13:6410-8.

Jörger M, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B, Schrijvers A, Twelves C, Beijnen J, Schellens J, Jodrell D, Izquierdo M, Sleeboom H, Huitema A, Richel D, Ditttrich C, Pavlidis N, Briasoulis E, Vermorken J, Strocchi E, Martoni A, Sorio R, EORTC-PAMM-NDDG. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. *Clinical pharmacokinetics* 2007; 46:1051-68.

Sparidans R, Bosch T, Jörger M, Schellens J, Beijnen J. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. *Journal of chromatography. B, Analytical technologies in the biomedical and life sciences* 2006; 839:45-53.

Jörger M, Huitema A, van den Bongard D, Schellens J, Beijnen J. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2006; 12:2150-7.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch